Chimeric antigen receptor (CAR) T-cell therapy has become a groundbreaking treatment option for multiple myeloma patients. However, despite the initial success of CAR T-cell therapy in reducing myeloma cells, myeloma can return within one to two years due to CAR T-cell depletion.
In response to this challenge, researchers have developed an innovative approach, the CAR-Enhancer (CAR-E) platform, designed to boost the longevity and efficacy of CAR T-cell therapy. This article explores how the CAR-E strategy could change the future of treatment for relapsed multiple myeloma patients by enhancing the activity, memory, and durability of CAR T cells.
CAR T-cell therapy reprograms a patient’s T cells to eliminate cancer more effectively. The process starts by extracting T cells from the patient's blood and genetically modifying them to produce a structure called a chimeric antigen receptor (CAR) that recognizes and binds to the B-cell maturation antigen (BCMA), a protein found on the surface of myeloma cells.
Learn more about CAR T cells and how they work with HealthTree University:
What are CAR-T cells? How are they made?
While this therapy has been highly effective, with nearly 100% of multiple myeloma patients initially responding, it’s common for myeloma cells to appear again. The primary reason for this is the inability of CAR T cells to remain in the bloodstream long enough to completely eradicate all cancer cells.
The CAR-E platform is a new way to extend the lifespan and potency of CAR T cells. It delivers a molecule that boosts the activity of CAR T cells from the outside.
It works with an immunomodulatory molecule called interleukin-2 (IL-2), which is fused with BCMA, the same protein that CAR T cells are designed to target. This "CAR-E" molecule enhances CAR T-cell function.
One of the most exciting aspects of the CAR-E strategy is its ability to generate a diverse collection of T cells, including effector T cells, which immediately attack cancer, and memory T cells. These are particularly valuable because they can persist long after the initial treatment, providing a lasting defense against cancer recurrence.
For multiple myeloma patients, the CAR-E platform offers several potential benefits:
These findings are based on tests performed directly on cells. While they offer promising results so far, the CAR-E platform still needs to be tested inclinical trials in real patients. These trials will focus on assessing the safety and dosing for CAR-E therapy.
If successful, this approach could dramatically improve outcomes for multiple myeloma patients who currently face a high risk of relapse following CAR T-cell therapy. The hope is that by integrating CAR-E into existing treatment regimens, patients can enjoy longer-lasting remissions, potentially transforming CAR T-cell therapy into a more durable solution to treat multiple myeloma.
Accelerate the discovery of new treatment options by connecting your records to HealthTree Cure Hub, an innovative tool that powers life-saving research!
If you are interested in participating in or finding a clinical trial, locating a myeloma specialist, or staying on top of your health by tracking your labs and securely connecting your medical records, you can create a free HealthTree Cure Hub account!
Sources:
Chimeric antigen receptor (CAR) T-cell therapy has become a groundbreaking treatment option for multiple myeloma patients. However, despite the initial success of CAR T-cell therapy in reducing myeloma cells, myeloma can return within one to two years due to CAR T-cell depletion.
In response to this challenge, researchers have developed an innovative approach, the CAR-Enhancer (CAR-E) platform, designed to boost the longevity and efficacy of CAR T-cell therapy. This article explores how the CAR-E strategy could change the future of treatment for relapsed multiple myeloma patients by enhancing the activity, memory, and durability of CAR T cells.
CAR T-cell therapy reprograms a patient’s T cells to eliminate cancer more effectively. The process starts by extracting T cells from the patient's blood and genetically modifying them to produce a structure called a chimeric antigen receptor (CAR) that recognizes and binds to the B-cell maturation antigen (BCMA), a protein found on the surface of myeloma cells.
Learn more about CAR T cells and how they work with HealthTree University:
What are CAR-T cells? How are they made?
While this therapy has been highly effective, with nearly 100% of multiple myeloma patients initially responding, it’s common for myeloma cells to appear again. The primary reason for this is the inability of CAR T cells to remain in the bloodstream long enough to completely eradicate all cancer cells.
The CAR-E platform is a new way to extend the lifespan and potency of CAR T cells. It delivers a molecule that boosts the activity of CAR T cells from the outside.
It works with an immunomodulatory molecule called interleukin-2 (IL-2), which is fused with BCMA, the same protein that CAR T cells are designed to target. This "CAR-E" molecule enhances CAR T-cell function.
One of the most exciting aspects of the CAR-E strategy is its ability to generate a diverse collection of T cells, including effector T cells, which immediately attack cancer, and memory T cells. These are particularly valuable because they can persist long after the initial treatment, providing a lasting defense against cancer recurrence.
For multiple myeloma patients, the CAR-E platform offers several potential benefits:
These findings are based on tests performed directly on cells. While they offer promising results so far, the CAR-E platform still needs to be tested inclinical trials in real patients. These trials will focus on assessing the safety and dosing for CAR-E therapy.
If successful, this approach could dramatically improve outcomes for multiple myeloma patients who currently face a high risk of relapse following CAR T-cell therapy. The hope is that by integrating CAR-E into existing treatment regimens, patients can enjoy longer-lasting remissions, potentially transforming CAR T-cell therapy into a more durable solution to treat multiple myeloma.
Accelerate the discovery of new treatment options by connecting your records to HealthTree Cure Hub, an innovative tool that powers life-saving research!
If you are interested in participating in or finding a clinical trial, locating a myeloma specialist, or staying on top of your health by tracking your labs and securely connecting your medical records, you can create a free HealthTree Cure Hub account!
Sources:
about the author
Jimena Vicencio
Jimena is an International Medical Graduate and a member of the HealthTree Writing team. She has a passion for languages and is currently learning Japanese. In her free time, she loves playing with her cats. Jimena is also pursuing a bachelor's degree in journalism.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.